Compare BIO & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIO | LEGN |
|---|---|---|
| Founded | 1952 | 2014 |
| Country | United States | United States |
| Employees | 7450 | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 5.9B |
| IPO Year | N/A | 2020 |
| Metric | BIO | LEGN |
|---|---|---|
| Price | $264.92 | $17.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | ★ $358.50 | $63.08 |
| AVG Volume (30 Days) | 235.7K | ★ 1.5M |
| Earning Date | 04-30-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.74 | $46.27 |
| Revenue Next Year | $3.05 | $28.77 |
| P/E Ratio | $9.72 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $211.43 | $16.24 |
| 52 Week High | $343.12 | $45.30 |
| Indicator | BIO | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 40.24 | 39.55 |
| Support Level | $239.33 | $16.24 |
| Resistance Level | $289.61 | $20.39 |
| Average True Range (ATR) | 7.46 | 0.80 |
| MACD | 0.44 | -0.09 |
| Stochastic Oscillator | 19.99 | 0.83 |
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.